LEADER 03392nam  22004815  450 
001 9910254481203321
005 20200705130622.0
010   $a3-319-50956-X
024 7 $a10.1007/978-3-319-50956-3
035   $a(CKB)3710000001124855
035   $a(DE-He213)978-3-319-50956-3
035   $a(MiAaPQ)EBC4830529
035   $a(PPN)199767688
035   $a(EXLCZ)993710000001124855
100   $a20170325d2017      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aLiquid Biopsies in Solid Tumors /$fedited by Massimo Cristofanilli
205   $a1st ed. 2017.
210  1$aCham :$cSpringer International Publishing :$cImprint: Humana,$d2017.
215   $a1 online resource (X, 161 p. 14 illus., 12 illus. in color.) 
225 1 $aCancer Drug Discovery and Development,$x2196-9906
311   $a3-319-50955-1 
320   $aIncludes bibliographical references at the end of each chapters and index.
327   $a1.Blood-based diagnostics in solid tumors: an overview -- 2.Circulating tumor cells (CTCs) in primary disease: the seed for metastasis -- 3.Enumeration and molecular analysis of CTCs in metastatic disease: The breast cancer model -- 4.Epithelial-Mesenchymal Transition (EMT) and cancer stem cells (CSCs): The traveling metastasis -- 5.Detection and monitoring of circulating immune cells in solid tumors: shifting priorities -- 6.Circulating-free tumor DNA (ctDNA): the real-time liquid biopsy -- 7.CTCs and ctDNA: two tales of a complex biology -- 8.Exosome: decoding the messaging system.
330   $aThis volume, with chapters written by experts in the field of cancerous tumors, details the key factors associated with liquid biopsies in solid tumors: blood-based diagnostics; circulating tumor cells; enumeration and molecular analysis (association with breast cancer); epithelialmesenchymal transition; detection and monitoring; circulating-free tumor DNA; CTCs and ctDNA; and the exosome. The field of blood-based diagnostics is rapidly evolving demonstrating the possibility of real-time molecular analysis of cancer cells and their phenotype and genotype. Circulating Tumor Cell (CTCs) have demonstrated prognostic and predictive value in advanced cancer and represents a source of tumor cells for transcriptome and genomic analysis. Most recently, the detection of genomic abnormalities in the peripheral blood by sensitive and selective PCR methods (liquid biopsy) opened to the option of a comprehensive blood-based tumor analysis. Similar information can be obtained by analysis of exosome, a natural packaging and messaging system being explored in advanced malignancies. The final frontier is the evaluation of immune cells determinant of innate and adaptive immunity.
410  0$aCancer Drug Discovery and Development,$x2196-9906
606   $aCancer research
606   $aCancer Research$3https://scigraph.springernature.com/ontologies/product-market-codes/B11001
615  0$aCancer research.
615 14$aCancer Research.
676   $a616.075705
702   $aCristofanilli$b Massimo$4edt$4http://id.loc.gov/vocabulary/relators/edt
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910254481203321
996   $aLiquid Biopsies in Solid Tumors$91759301
997   $aUNINA